Empiric Antibiotic Therapy for Community-Acquired Pneumonia

Treatment Approach for Hospitalized Non-ICU Patients

The Infectious Diseases Society of America recommends administering ceftriaxone 1-2g IV daily (or cefotaxime 1-2g IV q8h) combined with azithromycin 500mg IV daily as the preferred empiric regimen for hospitalized patients with moderate community-acquired pneumonia 1
This combination provides coverage against Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella) 2, 1
The β-lactam plus macrolide combination has strong evidence supporting improved outcomes in hospitalized CAP patients 1

The American College of Emergency Physicians and the Infectious Diseases Society of America recommend starting antibiotics immediately upon diagnosis, ideally while the patient is still in the emergency department 1
In patients with septic shock, antibiotic administration should occur as soon as possible after diagnosis 2
Do not delay treatment waiting for culture results 2

The Infectious Diseases Society of America recommends completing 7-10 days total of antibiotic therapy (combining IV and oral days) 1
Treatment should generally not exceed 8 days in a responding patient 2
Consider shorter durations guided by clinical improvement and biomarkers like procalcitonin 2

The combination regimen targets typical bacterial pathogens: S. pneumoniae (including drug-resistant strains), H. influenzae, Moraxella catarrhalis are covered by the β-lactam component 1
Atypical pathogens: Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila are covered by the macrolide component 2, 1

If aspiration pneumonia is suspected, consider adding anaerobic coverage with ampicillin-sulbactam instead of ceftriaxone 2
During influenza season or with compatible symptoms, add oseltamivir and ensure coverage for S. aureus (the most common cause of post-influenza bacterial pneumonia) 1